



Avastin® (bevacizumab)

Effective Date: January 1, 2021

Number: MG.MM.PH.70

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Avastin is a recombinant humanized monoclonal IgG1 antibody that binds to vascular endothelial growth factor (VEGF) and inhibits the proliferation of endothelial cells and the formation of new blood vessels.

Length of Authorization

Coverage will be provided for six months and may be renewed. For CNS cancers (Symptom management), coverage will be provided for 12 weeks and may NOT be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

Oncology indications (J9035):

- 170 billable units per 21 days
- 120 billable units per 14 days

Guideline

I. INITIAL APPROVAL CRITERIA

For Commercial, Medicaid, and Medicare members:

- Non-preferred agent: Avastin
- Preferred agents: Mvasi, Zirabev.

Coverage is provided for the following conditions (in addition to use supported by the National Comprehensive Cancer Network [NCCN] Clinical Practice Guidelines [NCCN Guidelines®] and/or NCCN

Drugs & Biologics Compendium [NCCN Compendium®] with a recommendation of category level 1 or 2A):*

- Patient is 18 years of age or older; **AND**
- Patient must have no recent history of hemorrhage or hemoptysis (the presence of blood in sputum); **AND**
- Patient must not have had a surgical procedure within the preceding 28 days or have a surgical wound that has not fully healed; **AND**
- **For newly started Avastin therapy, for Commercial, Medicaid, and Medicare members:**
Coverage may be considered medically necessary when:
 - Patient has experienced a therapeutic failure or intolerance with the plan-preferred medications (Mvasi AND Zirabev); **OR**
 - Avastin is requested for an indication for which the plan-preferred biosimilar agents (Mvasi or Zirabev) have not been FDA-approved OR are not supported by NCCN Guidelines® or NCCN Compendium® with a recommendation of category level 1 or 2A; **AND**

**Please note: Coverage for an appropriate biosimilar substitution will be allowed where NCCN Guidelines or Compendium state that an FDA-approved biosimilar is an appropriate substitution for bevacizumab.*

Colorectal Cancer (CRC) †

- Not used for adjuvant treatment; **AND**
- Patient's disease is metastatic, unresectable, or advanced; **AND**
 - Must be used as first- or second-line therapy in combination with a fluoropyrimidine- (e.g., 5-fluorouracil/5-FU or capecitabine) or irinotecan-based regimen; **OR**
 - Patient's disease has progressed on a first-line bevacizumab-containing regimen; **AND**
 - Used in combination with an irinotecan and/or oxaliplatin-based regimen (if not used first-line)

Non-squamous non-small cell lung cancer (NSCLC) †

- Patient's disease must be recurrent, unresectable, locally advanced, or metastatic; **AND**
 - Used as first-line therapy in combination with either carboplatin or cisplatin; **OR**
- Used for recurrent or metastatic disease in combination with carboplatin and paclitaxel or pemetrexed OR cisplatin and pemetrexed OR atezolizumab, carboplatin and paclitaxel; **AND**
 - Patient does not have locoregional recurrence without evidence of disseminated disease; **AND**
 - Used as first-line therapy for genomic tumor aberration (e.g., EGFR, ALK, ROS1, BRAF and PD-L1) negative or unknown OR BRAF V600E-mutation positive; **OR**
 - Used as subsequent therapy for genomic tumor aberration (e.g., EGFR, BRAF V600E, ALK, ROS1, PD-L1) positive and prior targeted therapy; **OR**
- Used as continuation maintenance therapy; **AND**

- Bevacizumab must have been included in patient's first-line chemotherapy regimen for recurrent or metastatic disease; **AND**
- Patient's disease has not progressed (achieved tumor response or stable disease) after first-line chemotherapy; **AND**
- Patient must have an ECOG performance status 0-2; **AND**
 - Used as a single agent; **OR**
 - Used in combination with pemetrexed if bevacizumab was previously used with a first-line pemetrexed/platinum chemotherapy regimen; **OR**
 - Used in combination with atezolizumab if bevacizumab was previously used first-line as part of atezolizumab/carboplatin/paclitaxel/bevacizumab regimen

Cervical Cancer †

- Patient's disease must be persistent, recurrent, or metastatic; **AND**
- Used in combination with paclitaxel **AND** either cisplatin, carboplatin, or topotecan

Breast cancer ‡

- Patient must have recurrent or metastatic disease; **AND**
- Patient has a high tumor burden or rapidly progressive disease; **AND**
- Must be used in combination with paclitaxel; **AND**
- Patient must be human epidermal growth factor receptor 2 (HER2)-negative; **AND**
 - Disease is hormone receptor-negative; **OR**
 - Disease is hormone receptor-positive and refractory to endocrine therapy; **OR**
 - Patient has symptomatic visceral disease or visceral crisis

Renal cell carcinoma (RCC) †

- Patient must have metastatic or relapsed disease; **AND**
 - Must be used in combination with interferon alfa †; **OR**
 - Must be used as a single agent for predominantly non-clear cell histology ‡; **OR**
 - Used in combination with erlotinib or everolimus in patients with papillary or hereditary leiomyomatosis disease

Central nervous system (CNS) cancer

- Used for symptom management related to radiation necrosis, poorly controlled vasogenic edema or mass effect as single-agent short-course therapy; **AND**
 - Patient has a diagnosis of one of the following other CNS cancers ‡:
 - Supratentorial Astrocytoma/Oligodendroglioma (Infiltrative, WHO Grade II); **OR**
 - Primary CNS Lymphoma; **OR**
 - Meningiomas; **OR**
 - Brain, Spine, or Leptomeningeal metastases; **OR**
 - Medulloblastoma; **OR**

- Recurrent Glioblastoma or Anaplastic Gliomas; **OR**
- Recurrent Intracranial or Spinal Ependymoma; **OR**
- Used as a single agent OR in combination with one of the following: irinotecan, carmustine, lomustine, or temozolomide in patients with recurrent Glioblastomas † or Anaplastic Gliomas ‡; **OR**
- Used as single agent therapy for patients with progressive disease who do not have subependymomas in patients with a diagnosis of recurrent Intracranial and Spinal Ependymoma ‡; **OR**
- Used for treatment of unresectable recurrent or progressive disease when radiation therapy is not an option in patients with a diagnosis of Meningiomas ‡

Ovarian cancer †

- Patient has malignant stage II-IV granulosa cell Sex Cord-Stromal Tumors ‡; **AND**
 - Used as single agent therapy for relapsed disease; **OR**
- Patient has Epithelial or Fallopian Tube or Primary Peritoneal Cancers †; **AND**
 - Patient has persistent or recurrent disease; **AND**
 - Avastin has not been used previously; **AND**
 - Patient has not had an immediate biochemical relapse; **AND**
 - Used as a single agent ‡; **OR**
 - If platinum sensitive, used in combination with carboplatin AND one of the following: gemcitabine or paclitaxel †; **OR**
 - If platinum resistant, used in combination with one of the following: PEGylated liposomal doxorubicin, weekly paclitaxel, or topotecan †; **OR**
 - Used as single agent maintenance therapy if used previously as part of combination therapy in patients with a partial or complete remission following primary therapy or therapy for platinum-sensitive recurrence; **OR**
 - Used as neoadjuvant therapy in combination with paclitaxel and carboplatin; **AND**
 - Patient has bulky stage III or IV disease or is a poor surgical candidate; **OR**
 - Used as adjuvant therapy in combination with paclitaxel and carboplatin; **AND**
 - Patient has stage II-IV disease; **OR**
 - Patient has stage I-IV carcinosarcoma histologic disease

Soft tissue Sarcoma ‡

- Used as a single agent for Angiosarcoma; **OR**
- Used in combination with temozolomide for Solitary Fibrous Tumor or Hemangiopericytoma

Endometrial Carcinoma ‡

- Used as a single agent therapy for disease that has progressed on prior cytotoxic therapy; **OR**
- Used in combination with carboplatin and paclitaxel for advanced or recurrent disease

Malignant Pleural Mesothelioma ‡

- Patient has unresectable or metastatic disease; **AND**
- Must be used in combination with pemetrexed and either cisplatin or carboplatin followed by single-agent maintenance therapy.

AIDS-Related Kaposi Sarcoma †

- Patient has relapsed or refractory disease; **AND**
- Patient has advanced cutaneous, oral, visceral or nodal disease; **AND**
- Used as subsequent therapy in combination with antiretroviral therapy (ART) after failure to two lines of systemic therapy

† FDA-labeled indication(s); ‡ Compendia recommended indication(s)

Genomic Aberration Targeted Therapies (<i>not all inclusive</i>) §
Sensitizing EGFR mutation-positive tumors <ul style="list-style-type: none"> – Erlotinib – Afatinib – Gefitinib – Osimertinib
ALK rearrangement-positive tumors <ul style="list-style-type: none"> – Crizotinib – Ceritinib – Brigatinib – Alectinib
ROS1 rearrangement-positive tumors <ul style="list-style-type: none"> – Crizotinib – Ceritinib
BRAF V600E-mutation positive tumors <ul style="list-style-type: none"> – Dabrafenib/Trametinib
PD-L1 expression-positive tumors (>50%) <ul style="list-style-type: none"> – Pembrolizumab

II. RENEWAL CRITERIA

Coverage can be renewed based upon the following criteria:

- Continuation of documented current and/or successful therapy with a non-preferred agent (Avastin); **AND**
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: gastrointestinal perforation, surgical/wound healing complications, hemorrhage, arterial and venous thromboembolic events (ATE & VTE), uncontrolled hypertension, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion reactions, ovarian failure, congestive heart failure (CHF), etc.; **AND**

CNS Cancers – symptom management (short-course therapy):

- May NOT be renewed

Metastatic carcinoma of the colon or rectum (additional renewal opportunity):

- Patient’s disease has progressed on a first-line bevacizumab-containing regimen; **AND**
 - Used in combination with an irinotecan and/or oxaliplatin-based regimen (if not used first line)

Malignant Pleural Mesothelioma – maintenance therapy:

- Must be used as a single agent

Ovarian cancer - Platinum sensitive disease or recurrence:

- Must be used as a single agent for maintenance therapy; **OR**
- Used in combination with chemotherapy, for completion of initial therapy, up to 10 cycles total

Non-squamous non-small cell lung cancer – continuation maintenance therapy:

- Avastin must have been included in patient’s 1st line chemotherapy; **AND**
- Patient must have an ECOG performance status 0-2; **AND**
 - Used as a single agent; **OR**
 - Used in combination with pemetrexed if Avastin was previously used with a 1st-line pemetrexed/platinum chemotherapy regimen

Dosing/Administration

Indication	Dose
CRC	5 to 10 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks
NSCLC & Cervical Cancer	15 mg/kg every 3 weeks until disease progression or unacceptable toxicity.
CNS Cancers	–For disease treatment: 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity. –For symptom management: 5-10 mg/kg every 2 weeks up to 12 weeks duration
RCC	10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
MPM	15 mg/kg every 3 weeks in combination with chemotherapy for up to 6 cycles followed by single agent use, at the same dose/frequency, until disease progression or unacceptable toxicity.
Ovarian Cancer	<u>Platinum-sensitive:</u> 15 mg/kg every 3 weeks for up to 8 cycles when used with paclitaxel or up to 10 cycles when used with gemcitabine; followed by single-agent bevacizumab 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity <u>Platinum-resistant:</u> 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity

All Other Oncology Indications	5-10 mg/kg every 2 weeks OR 7.5-15 mg/kg every 3 weeks
--------------------------------	---

Revision History

12/20/2020	<p>Clarifications:</p> <ul style="list-style-type: none"> Step therapy will apply to NEW starts only NCCN-supported use (with 1 or 2A recommendation) will be covered <p>Renewal criteria updated:</p> <ul style="list-style-type: none"> Removed: "Patient continues to meet criteria identified above" Added coverage: "Continuation of documented current and/or successful therapy with a non-preferred agent (Avastin)"
11/2/2020	Effective 01/01/2021 Member must fail trial of Mvasi AND Zirabev, prior to using Avastin (Medicare members are subject to this step therapy).
03/31/2020	Added to the Initial Criteria: Effective 07/01/2020, Mvasi and Zirabev are the preferred agents for Commercial and Medicaid members. Member must fail trial of Mvasi AND Zirabev, prior to using Avastin (Only Commercial and Medicaid members are subject to this step therapy).
2/12/2019	<p>Initial Criteria: Added Patient is 18 years of age or older.</p> <p>Added Diagnosis Codes C51.0, C51.1, C51.2, C51.8</p>

Authorization

Applicable Procedure Codes

J9035	Injection, bevacizumab, 10 mg; 1 billable unit = 10 mg
-------	--

Applicable NDC's

50242-0060-xx	Avastin single-use vial, 100 mg/4 mL solution for injection
50242-0061-xx	Avastin single-use vial, 400 mg/16 mL solution for injection

ICD-10	ICD-10 Description
C17.0	Malignant neoplasm duodenum
C17.1	Malignant neoplasm jejunum
C17.2	Malignant neoplasm ileum
C17.8	Malignant neoplasm of overlapping sites of small intestines
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure

C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of large intestines
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus or lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C38.4	Malignant neoplasm of pleura
C45.0	Mesothelioma of pleura
C46.0	Kaposi's sarcoma of skin
C46.1	Kaposi's sarcoma of soft tissue
C46.2	Kaposi's sarcoma of palate
C46.3	Kaposi's sarcoma of lymph nodes
C46.4	Kaposi's sarcoma of gastrointestinal sites
C46.50	Kaposi's sarcoma of unspecified lung
C46.51	Kaposi's sarcoma of right lung
C46.52	Kaposi's sarcoma of left lung
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma, unspecified
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum

C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola , unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast

C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri

C53.9	Malignant neoplasm of cervix uteri, unspecified
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C57.9	Malignant neoplasm of female genital organ, unspecified
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C70.0	Malignant neoplasm of cerebral meninges
C70.1	Malignant neoplasm of spinal meninges
C70.9	Malignant neoplasm of meninges, unspecified
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe

C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72.0	Malignant neoplasm of spinal cord
C72.9	Malignant neoplasm of central nervous system, unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
C83.30	Diffuse large B-cell lymphoma unspecified site
C83.31	Diffuse large B-cell lymphoma lymph nodes of head, face, and neck
C83.39	Diffuse large B-cell lymphoma extranodal and solid organ sites
C83.80	Other non-follicular lymphoma unspecified site
C83.81	Other non-follicular lymphoma lymph nodes of head, face, and neck
C83.89	Other non-follicular lymphoma extranodal and solid organ sites
D32.0	Benign neoplasm of cerebral meninges
D32.1	Benign neoplasm of spinal meninges
D32.9	Benign neoplasm of meninges, unspecified
D42.0	Neoplasm of uncertain behavior of cerebral meninges
D42.1	Neoplasm of uncertain behavior of spinal meninges
D42.9	Neoplasm of uncertain behavior of meninges, unspecified
D43.0	Neoplasm of uncertain behavior of brain, supratentorial
D43.1	Neoplasm of uncertain behavior of brain, infratentorial
D43.2	Neoplasm of uncertain behavior of brain, unspecified
D43.4	Neoplasm of uncertain behavior of spinal cord
I67.89	Other cerebrovascular disease
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.068	Personal history of other malignant neoplasm of small intestine
Z85.118	Personal history of other malignant neoplasm of bronchus and lung
Z85.3	Personal history of malignant neoplasm of breast

Z85.43	Personal history of malignant neoplasm of ovary
Z80.49	Family history of malignant neoplasm of other genital organs
Z85.528	Personal history of other malignant neoplasm of kidney
Z85.831	Personal history of malignant neoplasm of soft tissue
Z85.841	Personal history of malignant neoplasm of brain
Z85.848	Personal history of malignant neoplasm of other parts of nervous tissue

References

1. Avastin [package insert]. South San Francisco, CA; Genentech; June 2018. Accessed September 2019.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) bevacizumab. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed July 2018.
3. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. *Br J Cancer*. 2013 Aug 6; 109(3): 552–558
4. Delishaj D, Ursino S, Pasqualetti F, et al. Bevacizumab for the Treatment of Radiation-Induced Cerebral Necrosis: A Systematic Review of the Literature. *J Clin Med Res*. 2017 Apr; 9(4): 273–280.
5. National Government Services, Inc. Local Coverage Article for BEVACIZUMAB (e.g., Avastin™) - Related to LCD L33394 (A52370). Centers for Medicare & Medicaid Services, Inc. Updated on 2/23/2018 with effective date 3/1/2018. Accessed July 2018.
6. National Government Services, Inc. Local Coverage Determination (LCD): Drugs and Biologics, Coverage of, for Label and Off-Label Uses (L33394). Centers for Medicare & Medicaid Services, Inc. Updated on 11/22/2017 with effective date 12/1/2017. Accessed July 2018